Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of artificial tears and nonsteroidal anti-inflammatory drug (NSAID) eye drops, both administered topically to the eye. Artificial tears are lubricating solutions designed to mimic natural tear film, providing moisture and relief from dry eye symptoms by supplementing or stabilizing the tear film. They are typically available over-the-counter and may contain various polymers, electrolytes, or lipids to enhance ocular surface hydration[3]. Nonsteroidal anti-inflammatory drops (such as ketorolac, nepafenac, bromfenac, diclofenac) are prescription medications that reduce ocular inflammation and pain by inhibiting cyclooxygenase enzymes involved in prostaglandin synthesis[2][4][6][7]. This combination is commonly used for symptomatic relief in conditions like dry eye disease—where artificial tears address lubrication while NSAIDs target underlying inflammation—or post-surgical recovery where both comfort and control of inflammatory processes are needed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artificial tears + nonsteroidal anti-inflammatory drops.